Benitec Biopharma Limited (ASX:BLT)
Senior Vice President, Research & Development David Suhy presents at ASX Spotlight New York and London about the biotechnology company’s operations.
The technology of RNA Interference is driving a revolution in the treatment of cancer, ocular and genetic diseases. Benitec uses RNA Interference to work with the body's own cellular machinery to deliver therapies within the nucleus of target cells.
Benetic's one shot treatments promise to offer fast, cost effective therapies for some of medicine's most challenging diseases.